ABOS
Price
$1.58
Change
-$0.07 (-4.22%)
Updated
Nov 19, 01:29 PM (EDT)
Capitalization
99.95M
131 days until earnings call
Intraday BUY SELL Signals
LXRX
Price
$1.45
Change
-$0.02 (-1.36%)
Updated
Nov 19, 01:48 PM (EDT)
Capitalization
536.01M
119 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABOS vs LXRX

Header iconABOS vs LXRX Comparison
Open Charts ABOS vs LXRXBanner chart's image
Acumen Pharmaceuticals
Price$1.58
Change-$0.07 (-4.22%)
Volume$100
Capitalization99.95M
Lexicon Pharmaceuticals
Price$1.45
Change-$0.02 (-1.36%)
Volume$300
Capitalization536.01M
ABOS vs LXRX Comparison Chart in %
ABOS
Daily Signal:
Gain/Loss:
LXRX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ABOS vs. LXRX commentary
Nov 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and LXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 19, 2025
Stock price -- (ABOS: $1.65 vs. LXRX: $1.48)
Brand notoriety: ABOS and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 35% vs. LXRX: 52%
Market capitalization -- ABOS: $99.95M vs. LXRX: $536.01M
ABOS [@Biotechnology] is valued at $99.95M. LXRX’s [@Biotechnology] market capitalization is $536.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileLXRX’s FA Score has 1 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • LXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, LXRX is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 5 TA indicator(s) are bullish while LXRX’s TA Score has 4 bullish TA indicator(s).

  • ABOS’s TA Score: 5 bullish, 4 bearish.
  • LXRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than LXRX.

Price Growth

ABOS (@Biotechnology) experienced а -16.24% price change this week, while LXRX (@Biotechnology) price change was -5.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.28%. For the same industry, the average monthly price growth was -5.78%, and the average quarterly price growth was +64.80%.

Reported Earning Dates

ABOS is expected to report earnings on Mar 30, 2026.

LXRX is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Biotechnology (-2.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($536M) has a higher market cap than ABOS($99.9M). LXRX YTD gains are higher at: 99.729 vs. ABOS (-4.070). LXRX has higher annual earnings (EBITDA): -107.44M vs. ABOS (-132.35M). ABOS (143M) and LXRX (139M) have equal amount of cash in the bank . ABOS has less debt than LXRX: ABOS (30.1M) vs LXRX (57M). LXRX has higher revenues than ABOS: LXRX (58.4M) vs ABOS (0).
ABOSLXRXABOS / LXRX
Capitalization99.9M536M19%
EBITDA-132.35M-107.44M123%
Gain YTD-4.07099.729-4%
P/E RatioN/AN/A-
Revenue058.4M-
Total Cash143M139M103%
Total Debt30.1M57M53%
FUNDAMENTALS RATINGS
LXRX: Fundamental Ratings
LXRX
OUTLOOK RATING
1..100
10
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
98
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
16
SEASONALITY SCORE
1..100
30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSLXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 9 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signal:
Gain/Loss:
LXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APWEX17.70N/A
N/A
Cavanal Hill World Energy Investor
PRJBX46.96N/A
N/A
PGIM Jennison Global Opportunities R2
LHCCX21.36N/A
N/A
Lord Abbett Health Care C
HHDFX35.99N/A
N/A
Hamlin High Dividend Equity Instl
PXGAX25.79-0.19
-0.73%
Impax US Sustainable Economy A

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with BEAM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+4.43%
BEAM - ABOS
44%
Loosely correlated
-0.36%
CELC - ABOS
44%
Loosely correlated
-0.67%
CRBU - ABOS
43%
Loosely correlated
-0.79%
SYRE - ABOS
42%
Loosely correlated
-1.07%
CRSP - ABOS
40%
Loosely correlated
-3.34%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+1.03%
PLRX - LXRX
38%
Loosely correlated
-5.45%
OCUL - LXRX
38%
Loosely correlated
-1.09%
VCYT - LXRX
37%
Loosely correlated
-1.35%
ABOS - LXRX
35%
Loosely correlated
+4.43%
DNLI - LXRX
34%
Loosely correlated
+0.58%
More